论文部分内容阅读
目的探讨阿托伐他汀钙对类风湿关节炎(RA)患者血清C-反应蛋白(CRP)、白细胞介素(IL-6)、肿瘤坏死因子(TNF)-α的影响。方法采集类风湿关节炎初治患者43例(RA组)和年龄、性别匹配的正常者40例(对照组),比较两组临床及实验室炎性指标,予RA组口服阿托伐他汀钙片20mg,1次/d,疗程12周,再比较RA组服药前后的临床及实验室炎性指标,分析阿托伐他汀钙片对CRP、IL-6及TNF-α的影响。结果CRP、IL-6及TNF-α,RA组较对照组均明显升高(P<0.05),RA组服药后较服药前三者均明显降低(P<0.05)。结论RA存在全身性炎症反应,阿托伐他汀钙可减轻RA患者的炎症反应,控制这种炎症反应所促使的动脉粥样硬化。
Objective To investigate the effect of atorvastatin calcium on serum C-reactive protein (CRP), interleukin (IL-6) and tumor necrosis factor (TNF) -α in patients with rheumatoid arthritis (RA) Methods Forty-three patients with rheumatoid arthritis (RA group) and 40 age-matched and normal subjects (control group) were enrolled in this study. The clinical and laboratory inflammatory parameters were compared between two groups. Patients in RA group were given atorvastatin calcium 20 mg once daily for 12 weeks. The clinical and laboratory inflammatory indexes of RA group before and after treatment were compared. The effects of atorvastatin calcium tablets on CRP, IL-6 and TNF-α were analyzed. Results Compared with the control group, the levels of CRP, IL-6, TNF-α and RA in RA group were significantly increased (P <0.05). Conclusions There is systemic inflammatory reaction in RA. Atorvastatin calcium can reduce the inflammatory reaction in RA patients and control the atherosclerosis induced by this inflammatory reaction.